Quintiles Selected as Preferred Central Laboratory Provider by Bristol-Myers Squibb

  Quintiles Selected as Preferred Central Laboratory Provider by Bristol-Myers
  Squibb

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- April 11, 2013

Quintiles today announced that it has been chosen as a preferred provider by
Bristol-Myers Squibb Company (NYSE:BMY) to provide global support for
Bristol-Myers Squibb’s central lab work, biomarker testing and assay
development for the next five years.

“This agreement deepens the commitment our companies share to providing
patients access to effective, safe and affordable treatments,” said Thomas
Wollman, Senior Vice President of Quintiles Global Laboratories. “We look
forward to working with Bristol-Myers Squibb to bring personalized medicine
into mainstream drug development.”

About Quintiles

Quintiles is the world’s largest provider of biopharmaceutical development and
commercial outsourcing services with a network of more than 27,000 employees
conducting business in approximately 100 countries. We have helped develop or
commercialize all of the top-50, best-selling drugs on the market. Quintiles
applies the breadth and depth of our service offerings along with extensive
therapeutic, scientific and analytics expertise to help our customers navigate
an increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare outcomes.

Click here to subscribe to Mobile Alerts for Quintiles.

Contact:

Quintiles
Mari Mansfield, 919-998-2639
Corporate Communication
mari.mansfield@quintiles.com
or
Karl Deonanan, 919-998-2789
Investor Relations
karl.deonanan@quintiles.com
 
Press spacebar to pause and continue. Press esc to stop.